Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: jopawa who wrote (71826)	4/28/1999 9:42:00 AM
From: Michaelste	Read Replies (1) \| Respond to of 119973

For those interested in the Biotechs - ORTC Oscar Gruss Initiates Coverage on Ortec International With a BUY Rating NEW YORK, April 28 /PRNewswire/ -- The following is being issued by Oscar Gruss & Son Incorporated, a member of the National Association of Securities Dealers, CRD number 2091: Oscar Gruss & Son Incorporated initiates coverage on Ortec International Inc., New York, New York with a BUY rating. (Nasdaq-ORTC-$9). In a new report, Alan Tuchman, equity research analysts at Oscar Gruss, provides an examination of Ortec International (Ortec), a biotechnology company that researches, develops and markets products for the treatment of severe skin wound. Dr. Tuchman believes that Ortec is well positioned in the biotechnology industry, especially with its extensive research pipeline in areas of wound healing and constructive cosmetic surgery. Dr. Tuchman provides detailed analyses regarding his recommendation in a research report available from Oscar Gruss & Son Incorporated at 212-514-2345. Investment Ratings: STRONG BUY: expected total annual return of greater than 25% over the next 12-18 months; BUY: expected total annual return in the range of 15-25% over the next 12-18 months; SPECULATIVE BUY: stock for investors who can afford higher risks; expected total annual return of greater than 25% if anticipated contingencies materialize over the next 12 - 18 months with the potential for high return volatility, lower or negative total annual returns in this time period may be possible; HOLD: stock is fairly valued and may provide returns which approximate returns expected from the its peer group in the equity markets over the next 12-18 months, or perhaps less. Other factors considered in the Investment Ratings may include, but are not limited to, the company's risk profile, including earnings predictability, financial position, industry position, technology and product risks, management strengths, and other factors. The required annual return for a specific Investment Rating will be increased for stocks with greater financial, business, and/or earnings risk. This report is based upon information which Oscar Gruss & Son Incorporated (Oscar Gruss) believes to be reliable. However, neither Oscar Gruss nor any individual acting on the behalf of Oscar Gruss can guarantee the accuracy or completeness of its contents. It does not purport to contain a complete analysis of every material fact concerning any company, industry or security. Oscar Gruss assumes that it will be read in conjunction with other available reports and data. Opinions expressed herein are subject to change without notice. No investor can assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Oscar Gruss and/or our employees and affiliates may have positions in securities which are referred to herein and may make purchases or sales thereof while this report is in circulation. Oscar Gruss or one of its affiliates may from time to time perform investment banking or other services for, or solicit investment banking or other business from a company mentioned in this report. Further information is available upon request. Foreign-currency-denominated securities are subject to fluctuations in currency exchange rates that could have a positive or adverse effect on an investor's return upon the conversion into local currency of dividends or interest received, or proceeds from the sale of such securities. In addition, the value of U.S. dollar-denominated ADRs and the value of U.S. dollar-denominated ordinary shares, or common shares, of foreign issuers can be influenced by fluctuations in currency exchange rates. /CONTACT: Alan Tuchman, M.D., for Oscar Gruss & Son Incorporated, 212-514-2345/ 09:26 EDT